Welcome to our dedicated page for Turnstone Biologics news (Ticker: TSBX), a resource for investors and traders seeking the latest updates and insights on Turnstone Biologics stock.
The TSBX news page on Stock Titan provides an organized view of historical news and corporate announcements for Turnstone Biologics Corp., a biotechnology company that described itself as a clinical-stage developer of Selected tumor‑infiltrating lymphocyte (Selected TIL) therapies for solid tumors. These articles trace the evolution of Turnstone’s clinical programs, financial position, and ultimately its acquisition and delisting.
Readers can review clinical development updates, including initial data from the Phase 1 STARLING trial of TIDAL‑01 in metastatic microsatellite stable colorectal cancer, as well as reports on other Phase 1 studies in indications such as head and neck cancer and uveal melanoma. The news flow also covers preclinical data presentations at scientific meetings like the Society for Immunotherapy of Cancer (SITC), where Turnstone highlighted methods to enrich neoantigen‑reactive TIL and approaches to predict expansion of tumor‑reactive T cells.
The archive includes quarterly and annual financial result press releases, which discuss research and development expenses, general and administrative costs, and net losses typical of a clinical-stage biotechnology company. These releases also describe portfolio prioritization, corporate restructuring, and workforce reductions implemented to extend the company’s cash runway and focus resources on its TIDAL‑01 program.
Later news items document a significant strategic shift, including Turnstone’s decision to discontinue all clinical studies of TIDAL‑01, initiate a review of strategic alternatives, and engage a financial advisor. Subsequent announcements and related SEC filings outline the Agreement and Plan of Merger with XOMA Royalty Corporation, the tender offer for Turnstone’s shares, and the completion of the merger that resulted in Turnstone becoming a wholly owned subsidiary of XOMA and its common stock being removed from Nasdaq listing.
Investors and researchers can use this news history to understand how Turnstone’s clinical data, financial disclosures, restructuring actions, and corporate transactions unfolded over time. Bookmarking this page allows for quick reference to the key milestones that defined the lifecycle of TSBX as a public company.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.